ArticleAmerican journal of translational research2019
SPP1 functions as an enhancer of cell growth in hepatocellular carcinoma targeted by miR-181c.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 63 citations in OpenAlex.
- SPP1 knockdown inhibits invasion, migration and paclitaxel-induced Epithelial-Mesenchymal Transition in Cervical Cancer Cells through the TGF-β/Akt/Snail pathway.Scientific reports · 2026Article
- A prognostic signature of ferroptosis and lipid metabolism related genes predicts survival and immunotherapy response in hepatocellular carcinoma.Discover oncology · 2026Article
- SPP1 promotes the metastasis of liver cancer cells through modulation of the MT1L/vimentin axis.American journal of cancer research · 2026Article
- Early immune response toMicrobiology spectrum · 2025Article
- Identifying the Crucial Biomarker of MASH-Related HCC.Combinatorial chemistry & high throughput screening · 2025Article
- Predictive Prognostic Model for Hepatocellular Carcinoma Based on Seven Genes Participating in Arachidonic Acid Metabolism.Cancer medicine · 2024Article
- Altered immune pathways in patients of temporal lobe epilepsy with and without hippocampal sclerosis.Scientific reports · 2024Article
- Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma.Scientific reports · 2024Article
- Revealing cell-cell communication pathways with their spatially coupled gene programs.Briefings in bioinformatics · 2024Article
- Overexpression ofAging · 2024Article
- Comprehensive analysis of KLF2 as a prognostic biomarker associated with fibrosis and immune infiltration in advanced hepatocellular carcinoma.BMC bioinformatics · 2023Article
- Inflammatory bowel disease increases the risk of hepatobiliary pancreatic cancer: A two-sample Mendelian randomization analysis of European and East Asian populations.Cancer medicine · 2023Article
- Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways.BMC cancer · 2023Article
- Novel insights into the progression and prognosis of the calpain family members in hepatocellular carcinoma: a comprehensive integrated analysis.Frontiers in molecular biosciences · 2023Article
- A novel myeloid cell marker genes related signature can indicate immune infiltration and predict prognosis of hepatocellular carcinoma: Integrated analysis of bulk and single-cell RNA sequencing.Frontiers in molecular biosciences · 2023Article
- A Five-LLPS Gene Risk Score Prognostic Signature Predicts Survival in Hepatocellular Carcinoma.International journal of genomics · 2023Article
- Article
- In Silico and In Vivo Evaluation of microRNA-181c-5p's Role in Hepatocellular Carcinoma.Genes · 2022Article
- Secreted phosphoprotein 1 promotes angiogenesis of glioblastoma through upregulating PSMA expression via transcription factor HIF1α.Acta biochimica et biophysica Sinica · 2022Article
- SPP1 facilitates cell migration and invasion by targeting COL11A1 in lung adenocarcinoma.Cancer cell international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients diagnosed with hepatocellular carcinoma (HCC) suffered a high risk of recurrence and poor prognosis. Identification of differentially expressed genes (DEGs) in HCC provides potential biomarkers for evaluating prognosis and specific therapeutic treatments. In this study, DEGs over-expressed in HCC specimens with a fold change over 2.0 were collected through integrative bioinformatics analysis from GEO datasets. Gene ontology and KEGG pathway enrichment were conducted by applying DAVID database. We noticed Secreted phosphoprotein 1 (SPP1) as one of the signature genes up-regulated in HCC tissues with a close relation to the tumor process. Eighty-seven paired HCC specimens from our medical center were explored to verify the aberrant expression of SPP1 by IHC and qRT-PCR assay. Depletion of SPP1 in HCC Hep3B cells was established. The cell proliferation was impaired in SPP1 depleted cells, along with a resistance of cell apoptosis by down-regulating SPP1. Intriguingly, we further validated a direct interaction between miR-181c and SPP1, which indicated a post-transcriptional regulation mechanism of SPP1 in HCC. Thus, our results suggest that SPP1 may function as an enhancer of HCC growth targeted by miR-181c, and probably provide us an innovational target for HCC diagnose and therapeutic treatment.
Indexed as
Identifiers
31814897PMC6895505W2998367075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.